Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-11-08
2005-11-08
Desai, Rita (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S407000
Reexamination Certificate
active
06962923
ABSTRACT:
Compounds of formulae (IA) and (IB):wherein R1, R2, R3, Ar1and X are as defined above, are endothelin antagonists. The compounds are therefore useful in the treatment of a variety of conditions mediated by endothelin, such as restenosis, renal failure and systemic and pulmonary hypertension.
REFERENCES:
patent: 5541186 (1996-07-01), Breu et al.
patent: 5728706 (1998-03-01), Yamada et al.
patent: 5837708 (1998-11-01), Breu et al.
patent: 5856484 (1999-01-01), Breu et al.
patent: 5883092 (1999-03-01), Hirata et al.
patent: 6008224 (1999-12-01), Hirata et al.
patent: 0627423 (1993-01-01), None
patent: 0658548 (1994-12-01), None
patent: 0801062 (1995-12-01), None
patent: 0743307 (1996-05-01), None
patent: 0852226 (1996-09-01), None
patent: 0882719 (1996-12-01), None
patent: WO 9111172 (1991-08-01), None
patent: WO 9402518 (1994-02-01), None
patent: WO 9619455 (1996-06-01), None
patent: WO 9619459 (1996-06-01), None
patent: WO 9711942 (1997-04-01), None
patent: WO 9803488 (1998-01-01), None
patent: WO 9855148 (1998-12-01), None
Konishiroku et al., 1983, CAS:98:117056.
Lindley, et al., “Copper Assisted Nucleophilic Substitution of Aryl Halogen”,Tetrahedron40(9), pp. 1433-1456 (1984).
Neidlein, et al., “A Facile Synthesis of Dialkoxycarbonylketene-, Dicyanoketene-, and Alkoxycarbonyl(cyano)ketene Ethylene Acetals”,Synthesis, pp. 981-983 (1988).
Uno, et al., “A Convenient Synthesis of Alkyl Arylcyanoacetates by Palladium-Catalyzed Aromatic Substitutions”,Synthesis, pp. 506-508 (1985).
Neidhart, et al., “Discovery of RO-48-5695: A Potent-Mixed Endothelin Receptor Antagonist Optimized from Bosentan”,Bioorganic and Med. Chem. Letters7(17), pp. 2223-2228 (1997).
Corey, et al., “Formation of Olefins via Pyrolysis of Sulfonate Esters”,J. Org. Chem.54, pp. 389-393 (1989).
Strachan, et al., “Sustemic Blockade of the Endothelin-B Receptor Increases Peripheral Vascular Resistance in Healthy Men”,Hypertension33(1), pp. 581-585 (1999).
Saita, et al., “Mitogenic activity of endothelin on human cultures prostatic smooth muscle cells”,European Journal of Pharmacology349, pp. 123-128 (1998).
Krum, et al., “The effect of an Endothelin-Receptor Antagonist, Bosentan, on Blood Pressure in Patients with Essential Hypertension”,The New England Journal of Medicine,pp. 784-790 (1998).
Lerman, et al., “Circulating and Tissue Endothelin Immunoreactivity in Advanced Atheroslerosis”,The New England Journal of Medicine325(14), pp. 997-1001 (1991).
Tahara, et al., “Circulating immunoreactive Endothelin in Patients Undergoing Percutaneous Transluminal Coronary Angioplasty”,Metabolism40(12), pp. 1235-1237 (1991).
Murch, et al., “High endothelin-1 immunoreactivity in Crohn's disease and ulcerative colitis”,The Lancet339, pp. 381-385 (1992).
Douglas, et al., “Endothelin-1 Promotes Neointima Formation After Balloon Angioplasty in the Rat”,Journal of Cardivascular Pharmacology22(Suppl. 8), pp. S371-S373 (1993).
Berge, et al., “Pharmaceutical Salts”,Journal of Pharmaceutical Sciences66(1), pp. 1-19 (1977).
Stewart, et al., “Increased Plasma Endothelin-1 in Pulmonary Hypertension: Marker or Mediator or Disease?”,Annals of Internal Medicine114, pp. 464-469 (1991).
Yasuda, et al., “Circulating immunoreactive endothelin in ischemic heart disease”,American Heart Journal119(4), pp. 801-806 (1990).
Stockenhuber, et al., “Plasma levels of endothelin in chronic renal failure and after renal transplantation: impact on hypertension and cyclosporin A-associated nephrotoxicity”,Clinical Science82, pp. 255-258 (1992).
Stewart, et al., “Plasma endothelin in coronary enous blood from patients with either stable or unstable angina”,Br. Heart Journal66, pp. 7-9 (1991).
Nikolov, et al., “Cerebrovascular and CNS Effects of Endothelins—Target for Pharmacological Modification”,Drugs of Today28(5), pp. 303-310 (1992).
Ferres, “Pro-Drugs of β-Lactam Antibiotics”,Drugs of Today19(9), pp. 499-538 (1983).
Hurst, et al., “The Synthesis of Some 2-(Substituted) 5-Nitropyrimidines”,Heterocycles6(12), pp. 1999-2004 (1977).
Redington, et al., “Endothelin in Bronchoalveolar Lavage Fluid and Its Relation to Airflow Obstruction in Asthma”,Am J. Respir. Crit. Car Med.151, pp. 1034-1039 (1995).
Clark, et al., “Plasma endothelin levels in preclampsia: Elevation an d correlation with uric acid levels and renal impairment”,Am J. Obstet. Gynecol.166(3), pp. 962-968 (1992).
Tomita, et al.,Med Philos. 13(1), pp. 64-66 (1994).
Douglas, et al., “A Role for Endogenous Endothelin-1 in Neoinitmal Formation After Rat Carotid Artery Balloon Anioplasty”,Circulation Research75(1), pp. 190-197 (1994).
Sinkula, et al., “Prodrug Approach in Drug Design”,Annual Reports in Medicinal Chemistry10, pp. 306-316 (1975).
Hird, et al., “Palladium-catalysed cross-coupling reactions in the synthesis of some high polarizability materials”,Liquid Crystals14(3), pp. 741-761 (1993).
Collier, et al., “Plasma Endothelinlike Immunoractivity Levels in IDDM Patients with Microabluminuria”,Diabetes Care15(8), pp. 1038-1040 (1992).
Hurst, et al., “The Synthesis and Some Reactions of Chloropyrimidines”,,Heterocycles22(1), pp. 79-84 (1984).
Wempen, et al., “Pyrimidines VIII. Direct Nitration of Mono-oxopyrimidines (1)”,J. Heterocyclic Chem.6, pp. 593-595 (1969).
Clark, et al., “Acute Effect of Vasopressin on Plasma ANP Levels in Man”,AJH4(5, Part 2), p. 93A (1991).
Benamou, et al., “Variations in Systemic and Pulmonary Endothelin-1 in Horses with Recurrent Airway Obstruction (Heaves)”,Pulm. Pharm.&Therapeutics11, pp. 231-235 (1998).
Banks Bernard Joseph
Chubb Nathan Anthony Logan
Eshelby James John
Schulz Darren John
Desai Rita
Pfizer Inc.
Richardson Peter C.
Samuels Lisa A.
Shiao Robert
LandOfFree
Pyrazole compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrazole compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrazole compositions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3518295